Johnson & Johnson · Healthcare · Drug Manufacturers - General
Last price
US$ 276,22
▲ 1,43% on 06/11/2026FMP · on 06/11/2026
Payouts paid from 09/11/2025 to 09/11/2026 (the source has no record date), divided by the official close.
| Record date | Payment | Type | Status | US$ per share |
|---|---|---|---|---|
| — | 08/09/2026 | Dividend | paid | 1,34 |
| — | 09/06/2026 | Dividend | paid | 1,34 |
| — | 10/03/2026 | Dividend | paid | 1,30 |
| — | 09/12/2025 | Dividend | paid | 1,30 |
| Sum ÷ close of 06/11/2026 (US$ 276,22) | US$ 5,28 ÷ US$ 276,22 = 1,91% | |||
06/11/2026 · US$ 276,22
10/11/2025: US$ 188,41; 06/11/2026: US$ 276,22; mínima US$ 188,41, máxima US$ 278,43.
Fundamentals
25,04
Relação entre o preço da ação e o lucro por ação (LPA) informado pela fonte de dados.
Where it came from, when we collected it and what the number doesn't say. It's the data's origin, never a judgment on the asset.
8,15
Compara o preço de mercado de uma ação ou cota com o valor contábil/patrimonial por ação ou cota (VPA).
Where it came from, when we collected it and what the number doesn't say. It's the data's origin, never a judgment on the asset.
Income history
| Type | Ex-date | Payment date | Value/share |
|---|---|---|---|
| dividendo | — | 08/12/2026 | US$ 1,34 |
| dividendo | — | 08/09/2026 | US$ 1,34 |
| dividendo | — | 09/06/2026 | US$ 1,34 |
| dividendo | — | 10/03/2026 | US$ 1,30 |
| dividendo | — | 09/12/2025 | US$ 1,30 |
| dividendo | — | 09/09/2025 | US$ 1,30 |
| dividendo | — | 10/06/2025 | US$ 1,30 |
| dividendo | — | 04/03/2025 | US$ 1,24 |
| dividendo | — | 10/12/2024 | US$ 1,24 |
Context
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Indicators as of 28/12/2025. The 52-week low and high are official closes, not adjusted for distributions or corporate actions.See full chart
1,91%
Proventos da ação (ou rendimentos do FII) com data-com nos 365 dias anteriores ao cálculo, pagos ou já anunciados, em relação ao preço usado na coleta.
Where it came from, when we collected it and what the number doesn't say. It's the data's origin, never a judgment on the asset.
32,87%
Relação entre o lucro atribuível aos controladores e o patrimônio líquido atribuível aos controladores.
Where it came from, when we collected it and what the number doesn't say. It's the data's origin, never a judgment on the asset.
28,46%
De cada R$ 1,00 de receita, quanto sobra como lucro depois de todos os custos, despesas e impostos.
Where it came from, when we collected it and what the number doesn't say. It's the data's origin, never a judgment on the asset.
—
Quanto de lucro operacional (após impostos) a empresa gera para cada real de capital investido no negócio — próprio e de terceiros.
—
Quantos anos de geração de caixa operacional (EBITDA) a dívida líquida de uma empresa representa — uma medida de alavancagem.
US$ 11,03
Valor de lucro por ação informado pela fonte de dados da empresa.
Where it came from, when we collected it and what the number doesn't say. It's the data's origin, never a judgment on the asset.
US$ 33,87
Quanto do patrimônio contábil da empresa (ou do fundo) corresponde a cada ação ou cota.
Where it came from, when we collected it and what the number doesn't say. It's the data's origin, never a judgment on the asset.
21,2%
standard deviation of daily returns × √252 · 250 trading days · from 10/11/2025 to 06/11/2026 · source FMP
Where it came from, when we collected it and what the number doesn't say. It's the data's origin, never a judgment on the asset.
Reference: 28/12/2025 · All indicators: Financial Modeling Prep (FMP)
Net revenue (fiscal year)
US$ 94,2 bi
Cash (quarter)
US$ 19,7 bi
Market cap
US$ 664,9 bi
Operating cash flow (fiscal year)
—
| dividendo | — | 10/09/2024 | US$ 1,24 |